Pharmaceutical company intelligence

AJM Pharma (Pvt.) Limited

Manufacturer & importer Has products under both a manufacturing licence (DML) and a sale licence (DSL). Source: DRAP.

Private pharmaceutical company · Karachi · Pakistan

Karachi-based pharmaceutical company focused on specialty areas including oncology, thalassaemia, nephrology and gynaecology.

Sourced corporate profile Corporate identity fields are source-tracked; portfolio, price and competitor intelligence remains independently calculated by MedInfoBase.

Official website ↗ Official contact ↗

Evidence & freshness

What is sourced, and how recent is it?

Public-source corporate details

Latest regulatory-source observation26 Sep 2026Newest linked source record observed by MedInfoBase

Latest portfolio source check22 Sep 2026Latest source-check date across this published portfolio

Latest effective price date20 Aug 2026Newest effective date among published current price records

Corporate profile evidence4 sourcesCorporate source details checked 16 Aug 2026

Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.

Location intelligence

Company location

Google Maps

Location recorded

A sourced company location is recorded. Use the map link below for directions.

Open in Google Maps ↗

Intelligence snapshot

Portfolio at a glance

Not sales data · published MedInfoBase database view

Rx124public portfolio records represented

REG110unique registrations represented

IDX4indexed MedInfoBase presentations

SRC0additional source-observed presentations

R+0registry-only registrations

VER0registry-verified exact registrations

PKR124current validated price records

G61generic molecules in indexed catalogue

DF6dosage-form groups

TA9therapeutic areas

How to read these counts

RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.

PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.

IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.

Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.

Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.

Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.

Data coverage

How complete is this profile?

Current price coverage100%

public portfolio presentations with a validated current price

Official-source coverage100%

products linked back to a source record

Unit-price parse coverage98%

priced packs safely normalized per unit

Comparable-market coverage73%

products with at least one like-for-like comparator

Therapeutic classification100%

products assigned to a broad therapeutic area

Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent Price Position

Shows whether safely comparable products are below, near or above the peer median unit price.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

Oncology & immunology64 products · 52%

Anti-infectives31 products · 25%

Hematology & thrombosis10 products · 8%

Cardiovascular8 products · 6%

Respiratory & allergy3 products · 2%

Vaccines & immunologicals3 products · 2%

Gastrointestinal & hepatology2 products · 2%

CNS & mental health2 products · 2%

Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

Antineoplastic medicines63 products · 51%

Antivirals14 products · 11%

Erythropoiesis-stimulating agents6 products · 5%

Antimalarials5 products · 4%

Fluoroquinolone antibacterials5 products · 4%

Beta blockers4 products · 3%

Macrolide antibacterials4 products · 3%

Pulmonary surfactants3 products · 2%

Formulation footprint

Dosage forms

Tablet54 products

Injection46 products

Capsule18 products

Suspension3 products

Infusion2 products

Solution1 products

How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales

#1 LENMIDLenalidomide 12presentations 10 mg, 15 mg, 25 mg, 5 mg · Capsule #2 EPIAOErythropoietin 6presentations 10,000 IU/mL, 2,000 IU/mL, 4,000 IU/mL · Injection #3 OxaliplatinOxaliplatin 4presentations 100 mg, 100 mg/20 mL (5 mg/mL), 50 mg, 50 mg/10 mL · Injection #4 BLESBovine lipid extract surfactant (phospholipid) 3presentations 27 mg phospholipid/mL · Suspension #5 ConvideciaCOVID-19 vaccine (recombinant adenovirus type 5 vector) 3presentations >5×10^10 VP/0.5 mL, ≥5.0 × 10^10 viral particles/0.5 mL · Injection #6 IMATIBImatinib 3presentations 100 mg · Capsule

Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis

Below market median3640% of comparable products

Near market median36within ±5% of median

Above market median1921% of comparable products

Lowest-price equivalents27ties included

Company median price position -3.1% relative to the median unit price of like-for-like equivalent products.

Most competitively positioned examplesProducts with at least 3 market comparators

DOLUTEGRAVIR 50 mgDolutegravir · Tablet · 30's PKR 448.72/tablet-60.3% vs market median Cytocarb 150 mg/15 mLCarboplatin · Injection · 1's PKR 2,137.90/vial/unit-49.3% vs market median LAMIVIR 150 mgLamivudine · Tablet · 10's PKR 50.98/tablet-34.5% vs market median Zentavir 0.5 mgEntecavir · Tablet · 30's PKR 234.86/tablet-34.0% vs market median Zentavir 1 mgEntecavir · Tablet · 30's PKR 391.40/tablet-34.0% vs market median

How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

Pharmasol (Pvt) Ltd.257 products · 102 generics 28shared generics CCL Pharmaceuticals (Pvt.) Limited249 products · 99 generics 27shared generics Genome Pharmaceuticals (Pvt.) Ltd.181 products · 84 generics 24shared generics Pharmedic Laboratories (Pvt.) Ltd Lahore122 products · 70 generics 24shared generics AGP Limited225 products · 68 generics 23shared generics Nabiqasim Industries (Pvt) Ltd.,365 products · 118 generics 22shared generics

Regulatory & price activity

Observed database signals

Indexed registration numbers110Distinct registrations among indexed, published, presentation-validated products only

Verified price observations130

Products with a verified price124

Products with multiple price observations6

Source records with multiple versions124

Latest portfolio source check22 Sep 2026

Latest effective price date20 Aug 2026

Latest source observation26 Sep 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Company medicine portfolio

Medicine portfolio

110 unique registration(s) · 4 indexed presentation(s)

This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.

Intelligence filter: Therapeutic areaAnti-infectives Drug classMacrolide antibacterials Clear intelligence filters

Brand	Generic	Strength	Form	Pack	Registration	Source-listed price	Unit price	Price position
Athicin	Azithromycin	250 mg	Tablet	6's	114733	PKR 309.80	PKR 51.63/tablet	10% above median
Athicin	Azithromycin	500 mg	Tablet	6's	114734	PKR 567.96	PKR 94.66/tablet	12% above median
Thriomac	Clarithromycin	250 mg	Tablet	10's	114772	PKR 495.67	PKR 49.57/tablet	Near median
Thriomac	Clarithromycin	500 mg	Tablet	10's	114773	PKR 826.12	PKR 82.61/tablet	Near median

MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.

Cite this record

Manufacturer record

MedInfoBase. (2026). AJM Pharma (Pvt.) Limited — registered product portfolio in Pakistan [Data set]. MedInfoBase. Retrieved September 26, 2026, from https://medinfobase.com/company/aj-mirza-pharma-pvt-ltd/

Download .RIS Download .BIB EndNote, Zotero, Mendeley, RefWorks

Records change over time. Please cite the access date so readers can locate the version you used.

AJM Pharma (Pvt.) Limited

What is sourced, and how recent is it?

Company profile

Company location

Portfolio at a glance

How complete is this profile?

Downloadable company intelligence charts

Therapeutic Portfolio Mix

Dosage Form Portfolio

Equivalent Price Position

Closest Portfolio Competitors

Therapeutic areas

Drug classes

Dosage forms

Deepest brand families

Unit-price positioning vs equivalent products

Portfolio overlap

Observed database signals

Medicine portfolio

Cite this record